Abstract: The present application relates to a protein-drug conjugate, containing an antigen binding protein portion and a drug conjugate portion. The antigen binding protein portion comprises one or more antigen binding fragments, and at least two linker peptides are directly or indirectly connected to the antigen binding fragments. The two linker peptides can each independently contain a first cysteine Cys1 and a second cysteine Cys2. The drug conjugate portion is covalently bonded on Cys1. The present application further relates to a preparation method for the protein-drug conjugate, and a use for the protein-drug conjugate in preventing or treating tumors or other diseases.

Abstract: Provided an isolated antigen binding protein having one or more of the following properties: a. capable of binding to both human CD73 and Cynomolgus monkey CD73; b. capable of inhibiting 5?ectonucleotidase activity of CD73; c. capable of mediating CD73 internalization; d. capable of promoting T cell proliferation; e. with a relatively stable concentration in serum; and f. capable of inhibiting tumor growth and/or tumor cell proliferation. In addition, provided a method for producing the isolated antigen binding protein as well as pharmaceutical uses of the isolated antigen binding protein in preventing, alleviating and/or treating tumor.

Abstract: Disclosed is a binding protein having at least two protein functional regions, the binding protein comprising a protein functional region A and a protein functional region B; the protein functional region A and the protein functional region B target different antigens or epitopes, the protein functional region A is a Fab or a scFv structure, the protein functional region B is a VH structure, and there are one or more of each of the protein functional region A and the protein functional region B. A multi-specific binding protein has a smaller molecular weight, fewer polypeptide chains, and a simpler structure. By means of different structure types, relative positions, binding valence and other parameters, the functional activities for different targets can be adjusted, and then different combinations of activities can be designed so as to meet the needs of different dose combinations of clinical combinations.

Abstract: Provided is an anti-PD-L1 antigen binding protein, capable of binding to primate-derived PD-L1 with a KD value of 1×10?8 M or less. The antigen binding protein can block the binding of PD-1 and CD80 to PD-L1, stimulate the secretion of cytokines in immune cells, and can inhibit tumor growth and/or tumor cell proliferation. Also provided is a fusion protein, comprising human TGFBRII or a fragment thereof and the antigen binding protein. Also provided is an application of the antigen binding protein and/or the fusion protein in the prevention and treatment of tumors or cancers.

Abstract: Disclosed are isolated monoclonal antibodies, comprising a CD152-binding domain, wherein the antibodies bind specifically to human CD152. Methods of making and using the antibodies to treat diseases including cancers and autoimmune diseases are also provided.

Abstract: Disclosed are isolated monoclonal antibodies, comprising a CD152-binding domain, wherein the antibodies bind specifically to human CD152. Methods of making and using the antibodies to treat diseases including cancers and autoimmune diseases are also provided.